Clinical Cancer Research, Vol 3, Issue 8 1309-1316, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression

J Itakura, T Ishiwata, H Friess, H Fujii, Y Matsumoto, MW Buchler and M Korc
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, Irvine, California 92697, USA.

Vascular endothelial growth factor (VEGF) is an angiogenic polypeptide that has been implicated in cancer growth. In the present study, we characterized VEGF expression in cultured human pancreatic cancer cell lines and determined whether the presence VEGF in human pancreatic cancers is associated with enhanced neovascularization or altered clinicopathological characteristics. VEGF mRNA transcripts were present in all six tested cell lines (ASPC-1, CAPAN-1, MIA-PaCa-2, PANC-1, COLO-357, and T3M4). Immunoblotting with a highly specific anti-VEGF antibody revealed the presence of VEGF protein in all of the cell lines. Northern blot analysis of total RNA revealed a 5.2-fold increase in VEGF mRNA transcript in the cancer samples in comparison with the normal pancreas. Immunohistochemical and in situ hybridization analysis confirmed the expression of VEGF in the cancer cells within the tumor mass. Immunohistochemical analysis of 75 pancreatic cancer tissues revealed the presence of strong VEGF immunoreactivity in the cancer cells in 64% of the cancer tissues. The presence of VEGF in these cells was associated with increased blood vessel number, larger tumor size, and enhanced local spread but not with decreased patient survival. These findings indicate that VEGF is commonly overexpressed in human pancreatic cancers and that this factor may contribute to the angiogenic process and tumor growth in this disorder.

This article has been cited by other articles:

				S. A. Danovi, H. H. Wong, and N. R. Lemoine Targeted therapies for pancreatic cancer Br. Med. Bull., September 1, 2008; 87(1): 97 - 130. [Abstract] [Full Text] [PDF]

				K. Guo, V. Gokhale, L. H. Hurley, and D. Sun Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene Nucleic Acids Res., August 1, 2008; 36(14): 4598 - 4608. [Abstract] [Full Text] [PDF]

				S. K. Chang, I. Rizvi, N. Solban, and T. Hasan In vivo Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment Clin. Cancer Res., July 1, 2008; 14(13): 4146 - 4153. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, F. Nagashima, K. Shirao, and W. Koizumi Relationship between Expression of Vascular Endothelial Growth Factor in Tumor Tissue from Gastric Cancers and Chemotherapy Effects: Comparison between S-1 alone and the Combination of S-1 plus CDDP Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym057v1. [Abstract] [Full Text] [PDF]

				K. Cho, T. Ishiwata, E. Uchida, N. Nakazawa, M. Korc, Z. Naito, and T. Tajiri Enhanced Expression of Keratinocyte Growth Factor and Its Receptor Correlates with Venous Invasion in Pancreatic Cancer Am. J. Pathol., June 1, 2007; 170(6): 1964 - 1974. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, S. Yoshida, K. Shirao, Y. Shimada, I. Hyodo, H. Saito, Y. Miyata, and Gastrointestinal Oncology Study Group of Japan Cli Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin Jpn. J. Clin. Oncol., May 23, 2007; (2007) hym015v1. [Abstract] [Full Text] [PDF]

				M. C. Zatelli, D. Piccin, C. Vignali, F. Tagliati, M. R. Ambrosio, M. Bondanelli, V. Cimino, A. Bianchi, H. A Schmid, M. Scanarini, et al. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion Endocr. Relat. Cancer, March 1, 2007; 14(1): 91 - 102. [Abstract] [Full Text] [PDF]

				C. Bianco, E. Giovannetti, F. Ciardiello, V. Mey, S. Nannizzi, G. Tortora, T. Troiani, F. Pasqualetti, G. Eckhardt, M. de Liguoro, et al. Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7099 - 7107. [Abstract] [Full Text] [PDF]

				Y. Maruyama, M. Ono, A. Kawahara, T. Yokoyama, Y. Basaki, M. Kage, S. Aoyagi, H. Kinoshita, and M. Kuwano Tumor Growth Suppression in Pancreatic Cancer by a Putative Metastasis Suppressor Gene Cap43/NDRG1/Drg-1 through Modulation of Angiogenesis. Cancer Res., June 15, 2006; 66(12): 6233 - 6242. [Abstract] [Full Text] [PDF]

				A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]

				H. L. Kindler, G. Friberg, D. A. Singh, G. Locker, S. Nattam, M. Kozloff, D. A. Taber, T. Karrison, A. Dachman, W. M. Stadler, et al. Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer J. Clin. Oncol., November 1, 2005; 23(31): 8033 - 8040. [Abstract] [Full Text] [PDF]

				S. M. Weber Histological and Molecular Markers for Pancreatic Adenocarcinoma: Can They Help Us Define Which Patients Should Receive It? Ann. Surg. Oncol., March 1, 2005; 12(3): 200 - 201. [Full Text] [PDF]

				M. Kumar, Z.-R. Liu, L. Thapa, and R.-Y. Qin Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts Carcinogenesis, November 1, 2004; 25(11): 2075 - 2081. [Abstract] [Full Text] [PDF]

				I Esposito, M Menicagli, N Funel, F Bergmann, U Boggi, F Mosca, G Bevilacqua, and D Campani Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma J. Clin. Pathol., June 1, 2004; 57(6): 630 - 636. [Abstract] [Full Text] [PDF]

				M. Fukasawa and M. Korc Vascular Endothelial Growth Factor-Trap Suppresses Tumorigenicity of Multiple Pancreatic Cancer Cell Lines Clin. Cancer Res., May 15, 2004; 10(10): 3327 - 3332. [Abstract] [Full Text] [PDF]

				D. Wei, L. Wang, Y. He, H. Q. Xiong, J. L. Abbruzzese, and K. Xie Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity Cancer Res., March 15, 2004; 64(6): 2030 - 2038. [Abstract] [Full Text] [PDF]

				K. Fukahi, M. Fukasawa, G. Neufeld, J. Itakura, and M. Korc Aberrant Expression of Neuropilin-1 and -2 in Human Pancreatic Cancer Cells Clin. Cancer Res., January 15, 2004; 10(2): 581 - 590. [Abstract] [Full Text] [PDF]

				M. Bockhorn, Y. Tsuzuki, L. Xu, A. Frilling, C. E. Broelsch, and D. Fukumura Differential Vascular and Transcriptional Responses to Anti-Vascular Endothelial Growth Factor Antibody in Orthotopic Human Pancreatic Cancer Xenografts Clin. Cancer Res., September 15, 2003; 9(11): 4221 - 4226. [Abstract] [Full Text] [PDF]

				Q. Shi, X. Le, J. L. Abbruzzese, Z. Peng, C.-N. Qian, H. Tang, Q. Xiong, B. Wang, X.-C. Li, and K. Xie Constitutive Sp1 Activity Is Essential for Differential Constitutive Expression of Vascular Endothelial Growth Factor in Human Pancreatic Adenocarcinoma Cancer Res., May 1, 2001; 61(10): 4143 - 4154. [Abstract] [Full Text]

				I. Schwarte-Waldhoff, O. V. Volpert, N. P. Bouck, B. Sipos, S. A. Hahn, S. Klein-Scory, J. Luttges, G. Kloppel, U. Graeven, C. Eilert-Micus, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis PNAS, August 15, 2000; 97(17): 9624 - 9629. [Abstract] [Full Text] [PDF]

				S. J. Miknyoczki, H. Chang, A. Klein-Szanto, C. A. Dionne, and B. A. Ruggeri The Trk Tyrosine Kinase Inhibitor CEP-701 (KT-5555) Exhibits Significant Antitumor Efficacy in Preclinical Xenograft Modelsof Human Pancreatic Ductal Adenocarcinoma Clin. Cancer Res., August 1, 1999; 5(8): 2205 - 2212. [Abstract] [Full Text] [PDF]

				N. Liu, T. Furukawa, M. Kobari, and M.-S. Tsao Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma Am. J. Pathol., July 1, 1998; 153(1): 263 - 269. [Abstract] [Full Text] [PDF]